New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy

Theratechnologies announced the availability of Egrifta SV, a new single-vial formulation of tesamorelin for injection. Egrifta SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is supplied as a lyophilized powder in a 2mg single-dose vial with diluent and can be stored at room temperature. The more concentrated formulation allows for a smaller volume of administration (0.35mL). Egrifta SV and the original version, Egrifta, have differences in the dosage, the number of vials required to prepare a dose, reconstitution instructions, and storage…

Read More

Dolutegravir-Based Therapy Is Noninferior to Continued PI-Based Therapy in HIV

The presence of M184V or other archived nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations does not reduce the efficacy of dolutegravir-based therapy, which is noninferior to continued protease inhibitor (PI)-based therapy in HIV, according to study results published in the International Journal of Antimicrobial Agents. Current guidelines recommend that patients with HIV who experience virologic failure when receiving first-line non–NRTI-based antiretroviral therapy (ART) should start PI-based therapy to improve clinical outcomes. However, long-term use of PIs is associated with cardiovascular disease and several metabolic complications. The objective of this study…

Read More